Senderowicz A - Search Results

1

Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).

Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. Jäger W, et al. Among authors: senderowicz a. Life Sci. 2003 Oct 17;73(22):2841-54. doi: 10.1016/s0024-3205(03)00699-4. Life Sci. 2003. PMID: 14511769

2

In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.

Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, Senderowicz AM, Sausville EA, Jäger W. Hagenauer B, et al. Among authors: senderowicz am. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):407-14. Drug Metab Dispos. 2001. PMID: 11259324

3

Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver.

Jäger W, Zembsch B, Wolschann P, Pittenauer E, Senderowicz AM, Sausville EA, Sedlacek HH, Graf J, Thalhammer T. Jäger W, et al. Among authors: senderowicz am. Life Sci. 1998;62(20):1861-73. doi: 10.1016/s0024-3205(98)00152-0. Life Sci. 1998. PMID: 9600328

4

Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.

Bachrich T, Thalhammer T, Jäger W, Haslmayer P, Alihodzic B, Bakos S, Hitchman E, Senderowicz AM, Penner E. Bachrich T, et al. Among authors: senderowicz am. Hepatology. 2001 May;33(5):1053-9. doi: 10.1053/jhep.2001.24101. Hepatology. 2001. PMID: 11343231

5

Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.

Hagenauer B, Maier-Salamon A, Thalhammer T, Zöllner P, Senderowicz A, Jäger W. Hagenauer B, et al. Among authors: senderowicz a. Oncol Rep. 2004 May;11(5):1069-75. doi: 10.3892/or.11.5.1069. Oncol Rep. 2004. PMID: 15069549

6

The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.

Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. Jäger W, et al. Among authors: senderowicz a. Int J Clin Pharmacol Ther. 2003 Dec;41(12):610-1. doi: 10.5414/cpp41610. Int J Clin Pharmacol Ther. 2003. PMID: 14692715 No abstract available.

7

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Rudek MA, et al. Among authors: senderowicz am. Ann Pharmacother. 2003 Oct;37(10):1369-74. doi: 10.1345/aph.1C404. Ann Pharmacother. 2003. PMID: 14519054 Clinical Trial.

8

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM. Parker BW, et al. Among authors: senderowicz am. Blood. 1998 Jan 15;91(2):458-65. Blood. 1998. PMID: 9427698

9

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.

Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. Chao SH, et al. Among authors: senderowicz am. J Biol Chem. 2000 Sep 15;275(37):28345-8. doi: 10.1074/jbc.C000446200. J Biol Chem. 2000. PMID: 10906320

10

Assays for cyclin-dependent kinase inhibitors.

Senderowicz AM. Senderowicz AM. Methods Mol Biol. 2004;285:69-78. doi: 10.1385/1-59259-822-6:069. Methods Mol Biol. 2004. PMID: 15269400 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results